Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.
Nuvation Bio Inc (NUVB) is a clinical-stage biopharmaceutical company pioneering novel therapies for challenging cancers through innovative platforms like BD2-selective BET inhibitors and Drug-Drug Conjugate technology. This page serves as the definitive source for tracking the company’s progress in oncology research and corporate developments.
Investors and industry observers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships. All press releases and news articles are organized to provide clear insights into Nuvation Bio’s work targeting epigenetic regulators and advanced drug delivery systems.
Key content includes updates on lead candidate NUV-868, financial results, and scientific presentations. The page is regularly updated to reflect the most current information about the company’s efforts to develop precision oncology treatments.
Bookmark this page to stay informed about Nuvation Bio’s advancements in creating therapies for tumors resistant to conventional treatments. Check back frequently for verified updates directly from corporate communications and trusted industry sources.
Nuvation Bio (NYSE: NUVB) provided a corporate update ahead of the J.P. Morgan Healthcare Conference on January 11, 2022. The company anticipates multiple trial initiations and IND filings in 2022, including Phase 2 studies for NUV-422 and a Phase 1 study for NUV-868. Nuvation Bio reported a strong balance sheet with approximately $765 million in cash as of December 31, 2021. The CEO, David Hung, emphasized continued advancements in oncology therapeutics to address unmet patient needs in challenging cancer types.
Nuvation Bio (NYSE: NUVB) announced that the FDA has granted Fast Track designation to its investigational drug NUV-422, aimed at treating high-grade gliomas, including glioblastoma multiforme. This designation highlights the unmet needs in brain cancer treatment and allows for expedited development and communication with the FDA. NUV-422 also received Orphan Drug Designation in Q1 2021. Currently, the drug is undergoing Phase 1/2 trials, with promising preclinical results showing effective blood-brain barrier penetration. The company focuses on developing innovative oncology therapies.
Nuvation Bio Inc. (NYSE: NUVB) has received FDA clearance for its investigational new drug (IND) application to evaluate NUV-422, a CDK 2/4/6 inhibitor, for prostate cancer treatment. This marks the third IND approval after previous clearances for high-grade gliomas and advanced breast cancer. The company plans to initiate a Phase 1b/2 study focusing on metastatic castration-resistant prostate cancer (mCRPC) patients who previously underwent treatment with abiraterone acetate. The clinical trial will assess the safety and efficacy of NUV-422 combined with enzalutamide.
Nuvation Bio Inc. (NYSE: NUVB) announced the FDA's clearance of its IND application for NUV-422, a CDK 2/4/6 inhibitor aimed at treating advanced breast cancer. This marks a significant advancement as it follows the acceptance of NUV-422 for high-grade gliomas in 2020. The company will initiate a Phase 1/2 study on patients with HR+/HER2- advanced breast cancer who have undergone prior hormonal therapy. Nuvation Bio plans to share data from ongoing studies in late 2022, highlighting its commitment to developing innovative cancer therapies.
Nuvation Bio Inc. (NYSE: NUVB) reported Q3 financial results, showing a net loss of $22.0 million, or $(0.11) per share, compared to a net loss of $11.0 million, or $(0.12) per share in Q3 2020. R&D expenses surged to $17.1 million from $8.6 million due to increased research services and personnel costs. G&A expenses also rose to $5.7 million from $2.9 million. As of September 30, 2021, the company had $791.8 million in cash and marketable securities. Nuvation is advancing its CDK inhibitor program NUV-422, with top-line data expected in 2022.
Nuvation Bio Inc. (NYSE: NUVB) has reported its financial results for Q2 2021, highlighting significant progress in its drug development pipeline. The company is conducting a Phase 1/2 study of NUV-422, expanding patient enrollment to include those with recurrent glioblastoma and other cancers. Financially, Nuvation Bio holds $806.6 million in cash and equivalents. Q2 R&D expenses rose to $14 million from $7.3 million year-over-year, while general and administrative expenses increased to $6.4 million. The net loss for the quarter was $19.3 million, or $(0.09) per share, compared to a net loss of $8.6 million in Q2 2020.
Nuvation Bio Inc. (NYSE: NUVB) announced the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer. Dr. Hanley will oversee all aspects of pharmaceutical development, including supply chain and product manufacturing, while collaborating with various teams on commercial planning.
Dr. Hanley brings 20 years of experience from leading roles at BioXcel Therapeutics and Radius Health, focusing on oncology and drug development. His expertise is expected to enhance Nuvation Bio's ongoing Phase 1/2 study of lead candidate NUV-422 and strengthen technical operations.
Nuvation Bio (NYSE: NUVB) announced that Dr. David Hung, CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 9:00 a.m. ET. The event will be available for live viewing on the company's website under 'Events & Presentations' and archived for 30 days post-event. Nuvation Bio focuses on developing innovative oncology therapies, with a portfolio of six distinct product candidates aimed at challenging cancer types. Founded in 2018, Nuvation Bio is headquartered in New York and San Francisco.
Nuvation Bio Inc. (NYSE: NUVB) reported its Q1 2021 financial results, showing a net loss of $20.4 million, or $(0.12) per share, compared to a loss of $8.7 million, or $(0.10) per share, in Q1 2020. The company has cash reserves of $824.7 million to support its clinical development, including ongoing Phase 1/2 trials of NUV-422 in high-grade gliomas. Nuvation Bio plans to submit five additional IND applications by 2026. Additionally, it announced a restatement of Panacea’s 2020 financial statements due to SEC guidance on warrant accounting.
Nuvation Bio Inc. (NYSE: NUVB) reports strong financial results and an optimistic outlook following its merger with Panacea Acquisition Corp. in February 2021.
The company holds approximately $830 million in cash and is focused on advancing its oncology pipeline.
Currently, it is conducting a Phase 1/2 study of its lead compound, NUV-422, which has received FDA's Orphan Drug Designation for malignant gliomas.
Nuvation Bio expects to submit up to five additional Investigational New Drug applications by 2026.
